Patients with HER2-positive advanced breast cancers had the greatest benefits, with survival improvements ranging from ...

Peer-reviewed study in Cell Reports Medicine demonstrates that N17350 delivers selective, immune-activating tumor killing across solid tumor types -- N17350 targets a cancer vulnerability, via the ...

Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full ...

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemons ...

AstraZeneca's net profit in Q3 2025 was $2.54 billion, or $1.64 per share, compared to $1.43 billion, or $.92 per share, in Q3 2024. The firm beat the Wall Street consensus EPS estimate of $1.13.

Hengrui, one of China's leading pharmaceutical companies, is preparing to bring its cancer therapies to international markets ...

The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&GreenCNS ...

As we move into the final stretch of the year, stocks continue to grind higher, with the S&P 500 now up 16% year-to-date. Once again, it’s Big Tech leading the charge – the mega-cap innovators ...

A new molecule developed by researchers at Oregon Health & Science University offers a promising avenue to treat intractable ...

Triple-negative breast cancer is one of the most aggressive and difficult cancers to treat. It can initially respond well to ...

A cellular resistance mechanism at the origin of relapses of triple-negative breast cancer has recently been discovered by ...